You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
|
|---|---|
| Published in |
Journal of Clinical Oncology, November 2015
|
| DOI | 10.1200/jco.2015.63.9443 |
| Pubmed ID | |
| Authors |
Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Brett Hughes, Hervé Lena, Denis Moro-Sibilot, Alessandra Bearz, Santiago Viteri Ramirez, Tarek Mekhail, Alexander Spira, Walter Bordogna, Bogdana Balas, Peter N Morcos, Annabelle Monnet, Ali Zeaiter, Dong-Wan Kim |
| Abstract |
Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC. Alectinib 600 mg was administered orally twice daily. The primary end point was objective response rate (ORR) by central independent review committee (IRC). Of the 138 patients treated, 84 patients (61%) had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC. ORR by IRC was 50% (95% CI, 41% to 59%), and the median duration of response (DOR) was 11.2 months (95% CI, 9.6 months to not reached). In 96 patients (79%) previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55%). Median IRC-assessed progression-free survival for all 138 patients was 8.9 months (95% CI, 5.6 to 11.3 months). CNS disease control rate was 83% (95% CI, 74% to 91%), and the median CNS DOR was 10.3 months (95% CI, 7.6 to 11.2 months). CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%). Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43%) had a complete CNS response. At 12 months, the cumulative CNS progression rate (24.8%) was lower than the cumulative non-CNS progression rate (33.2%) for all patients. Common adverse events were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2. Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases. |
X Demographics
The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 19% |
| Spain | 1 | 5% |
| Belgium | 1 | 5% |
| Canada | 1 | 5% |
| Turkey | 1 | 5% |
| Mexico | 1 | 5% |
| United Kingdom | 1 | 5% |
| Korea, Republic of | 1 | 5% |
| Italy | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 9 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 16 | 76% |
| Practitioners (doctors, other healthcare professionals) | 3 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
| Scientists | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 260 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Brazil | 2 | <1% |
| France | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 254 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 52 | 20% |
| Other | 38 | 15% |
| Student > Bachelor | 28 | 11% |
| Student > Ph. D. Student | 24 | 9% |
| Student > Master | 23 | 9% |
| Other | 49 | 19% |
| Unknown | 46 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 129 | 50% |
| Biochemistry, Genetics and Molecular Biology | 21 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 6% |
| Agricultural and Biological Sciences | 14 | 5% |
| Neuroscience | 4 | 2% |
| Other | 18 | 7% |
| Unknown | 58 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,067,931
of 25,371,288 outputs
Outputs from Journal of Clinical Oncology
#2,594
of 22,043 outputs
Outputs of similar age
#17,658
of 393,281 outputs
Outputs of similar age from Journal of Clinical Oncology
#40
of 211 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,043 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 393,281 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 211 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.